AGN193109 Inhibitor – AGN 193109

Name: AGN193109 Inhibitor; AGN 193109; MyBioSource
Brand: MyBioSource
SKU: MBS5764353
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764353

AGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2nM, 2nM, and 3nM for RARalpha, RARbeta, and RARgamma). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

AGN 193109 (AGN193109), Inhibitor

Full Product Name

AGN 193109

Product Gene Name

AGN193109, inhibitor

Form/Format

Solid. Powder

Purity/Purification

99.89%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

392.49

Solubility

DMSO: 2mg/mL (5.10mM)
Need warming
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C28H24O2

SMILES

Cc1ccc(cc1)C1=CCC(C)(C)c2ccc(cc12)C#Cc1ccc(cc1)C(O)=O

CAS Number

171746-21-7

Cell Research

Cells (10,000/cm2) are seeded in complete medium and allowed to attach overnight. The cells are then shifted to defined medium (DM), allowed to equilibrate for 24 hours, and treatment,is initiated by the addition of fresh DM or DM containing epidermal growth factor (EGF) or retinoid. After 3 days of daily treatment with retinoid, the cells are harvested with 0.025% trypsin, 1mM EDTA, fixed in isotonic buffer containing 4% formaldehyde, and counted using a counter [2].

In Vitro

AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs [1]. AGN 193109 (100nM) inhibits the TTNPB (a retinoic acid receptor agonist)-dependent morphological change in ECE16-1 cells. AGN193109 half-reverses retinoid-dependent growth suppression at 10nM, and completely shows this effect at 100nM in ECE16-1 cells. AGN193109 (100nM) also eliminates TTNPB-induced decrease in levels of K5, K6, K14, K16, and K17 and increases in levels of K7, K8, and K19 [2].

Product Categories/Family for AGN193109, inhibitor

Metabolism; Retinoid Receptor

Product References and Citations for AGN193109, inhibitor

Johnson AT, et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem. 1995 Nov 24;38(24):4764-7.
Johnson AT, et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem. 1995 Nov 24;38(24):4764-7.
Agarwal C, et al. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J Biol Chem. 1996 May 24;271(21):12209-12.
Agarwal C, et al. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J Biol Chem. 1996 May 24;271(21):12209-12.
Standeven AM, et al. Specific antagonist of retinoid toxicity in mice. Toxicol Appl Pharmacol. 1996 May;138(1):169-75.
Standeven AM, et al. Specific antagonist of retinoid toxicity in mice. Toxicol Appl Pharmacol. 1996 May;138(1):169-75.

Other Notes

Small volumes of AGN193109, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for AGN193109 purchase

MBS5764353 is an inhibitor targeting AGN193109. Also known as AGN 193109.